secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001558370-23-018125
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences appoints Peter Anastasiou to Board of Directors
-------------------------------------------------------------------

- Appointed as Class III director effective November 5, 2023; term expires at 2026 annual meeting.
- Board expanded from nine to ten members; Anastasiou deemed independent.
- Anastasiou is CEO of Capsida Biotherapeutics and former President of North America at Lundbeck.
- Will serve on Compensation Committee; brings CNS and business development expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023018125/0001558370-23-018125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023018125/hrmy-20231105x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer